AKB-9778: Additional Phase Ib/IIa data

Additional data from the open-label, dose-escalation, U.S. Phase Ib/IIa TIME-1 trial in 18 evaluable patients with DME showed

Read the full 183 word article

How to gain access

Continue reading with a
two-week free trial.